Intranasal Ketamine For Pain Control In Patients With Sickle Cell Disease And Vaso-occlusive Episode (VOE) In The PED
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This will be a descriptive cohort study of intranasal ketamine as the initial analgesic for
children with sickle cell disease who present to the pediatric emergency department with
vaso-occlusive crisis and are awaiting intravenous line placement.